FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Avista Capital Managing Member IV, LLC
2. Issuer Name and Ticker or Trading Symbol

Organogenesis Holdings Inc. [ ORGO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

11/20/2020
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A common stock 11/20/2020  P  2739 (2)(3)A$4.9911 (4)29924415 I See Notes (1)(6)(7)
Class A common stock 11/24/2020  P  100 (5)A$5 29924515 I See Notes (1)(6)(7)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) This statement is being filed by the following Reporting Persons: Avista Acquisition Corp. (the "Sponsor"); Avista Acquisition LLC, which is the sole shareholder of the Sponsor; Avista Capital Partners IV, L.P. ("ACP Onshore"); Avista Capital Partners (Offshore) IV, L.P. ("ACP Offshore"); Avista Capital Partners IV GP, L.P. ("Avista GP"), which is the general partner of ACP Onshore and ACP Offshore; Avista Capital Managing Member IV, LLC, which is the general partner of Avista GP; Thompson Dean; and David Burgstahler.
(2) The number of securities reported represents an aggregate number of shares of Class A common stock of the Issuer ("Common Stock") purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. Each Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, the Issuer, or a stockholder of the Issuer, upon request, the number of shares of Common Stock purchased by the Reporting Person at each separate price within the range.
(3) Represents an aggregate of 1,373 shares of Common Stock purchased by ACP Onshore and 1,366 shares of Common Stock purchased by ACP Offshore.
(4) Purchase prices range from $4.98 to $5.00 per share, inclusive.
(5) Represents an aggregate of 50 shares of Common Stock purchased by ACP Onshore and 50 shares of Common Stock purchased by ACP Offshore.
(6) Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Joshua Tamaroff, an employee of an affiliate of the Reporting Persons, serves on the board of directors of the Issuer as a representative of the Reporting Persons.
(7) Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests

Remarks:
Exhibit 99.1 Joint Filer Information, incorporated herein by reference.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Avista Capital Managing Member IV, LLC
C/O AVISTA CAPITAL PARTNERS
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
XX

Avista Acquisition Corp.
65 EAST 55TH STREET
18TH FLOOR
NEW YORK, NY 10022
XX

Avista Acquisition, LLC
65 EAST 55TH STREET
18TH FLOOR
NEW YORK, NY 10022
XX

Avista Capital Partners IV, L.P.
C/O AVISTA CAPITAL PARTNERS
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
XX

Avista Capital Partners (Offshore) IV, L.P.
C/O AVISTA CAPITAL PARTNERS
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
XX

Avista Capital Partners IV GP, L.P.
C/O AVISTA CAPITAL PARTNERS
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
XX

Dean Thompson
C/O AVISTA CAPITAL PARTNERS
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
XX

Burgstahler David F
C/O AVISTA CAPITAL PARTNERS
65 EAST 55TH STREET, 18TH FLOOR
NEW YORK, NY 10022
XX


Signatures
See Exhibit 99.1 for Signatures incorporated herein by reference11/24/2020
**Signature of Reporting PersonDate

Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Organogenesis Charts.
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Organogenesis Charts.